Pulmonx (NASDAQ:LUNG) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of Pulmonx (NASDAQ:LUNG) from a hold rating to a sell rating in a report published on Friday morning.

A number of other research firms have also weighed in on LUNG. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research report on Saturday, September 27th. D. Boral Capital restated a “buy” rating and set a $16.00 target price on shares of Pulmonx in a research report on Monday, September 8th. Lake Street Capital dropped their target price on shares of Pulmonx from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Piper Sandler lowered shares of Pulmonx from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $9.00 to $2.50 in a research report on Thursday, July 31st. Finally, Wells Fargo & Company dropped their target price on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.66.

Pulmonx Stock Performance

LUNG opened at $1.84 on Friday. The firm has a market cap of $74.98 million, a P/E ratio of -1.29 and a beta of 0.42. Pulmonx has a 1-year low of $1.47 and a 1-year high of $9.37. The company has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $3.27. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. The business had revenue of $23.86 million during the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. Equities analysts forecast that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pulmonx

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in shares of Pulmonx by 58.8% in the fourth quarter. Bank of America Corp DE now owns 55,237 shares of the company’s stock valued at $375,000 after acquiring an additional 20,458 shares during the period. Rhumbline Advisers raised its stake in shares of Pulmonx by 4.6% in the first quarter. Rhumbline Advisers now owns 55,958 shares of the company’s stock valued at $377,000 after acquiring an additional 2,455 shares during the period. Vontobel Holding Ltd. purchased a new stake in shares of Pulmonx in the first quarter valued at $82,000. Legato Capital Management LLC purchased a new stake in shares of Pulmonx in the first quarter valued at $606,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Pulmonx in the first quarter valued at $2,041,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.